Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.
AIDS
; 20(11): 1558-60, 2006 Jul 13.
Article
em En
| MEDLINE
| ID: mdl-16847414
ABSTRACT
Darunabir, formerly TMC114, is a new protease inhibitor (PI) under clinical development designed to be active against HIV strains resistant to currently available PI. The virological and immunological response to ritonavir-boosted darunabir was assessed in four heavily antiretroviral-experienced patients who had failed enfuvirtide and two or more previous ritonavir-boosted PI regimens, including tipranavir in one instance. All four patients reached undetectable plasma HIV-RNA levels within 8 weeks of therapy and experienced significant CD4 cell count gains.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Sulfonamidas
/
Infecções por HIV
/
HIV-1
/
Inibidores da Protease de HIV
/
Ritonavir
Limite:
Humans
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article